Abstract: Compositions and methods for making and using anti-LPA agents, for example, monoclonal antibodies, are described. Variable domain and complementarity determining region amino acid sequences of several monoclonal antibodies against LPA are disclosed, as is a consensus anti-LPA monoclonal antibody variable domain sequence.

Abstract: Methods are provided for using antibodies and antibody fragments that bind one or more cysteinyl leukotrienes (cysLTs) for treatment of diseases, including inflammatory, respiratory and gastrointestinal diseases and conditions associated with aberrant levels of one or more cysLTs. Anti-cysLT antibodies and antigen-binding antibody fragments, and compositions containing such antibodies and antibody fragments, are also provided.

Abstract: Compositions and methods for making and using anti-LPA agents, for example, monoclonal antibodies, are described. Variable domain and complementarity determining region amino acid sequences of several monoclonal antibodies against LPA are disclosed, as is a consensus anti-LPA monoclonal antibody variable domain sequence.

Abstract: Methods are provided for using antibodies that bind one or more cysteinyl leukotrienes (cysLTs) for treatment of diseases, including inflammatory diseases and asthma, associated with aberrant levels of one or more cysLTs. Anti-cysLT antibodies and antigen-binding antibody fragments, and compositions containing such antibodies and antibody fragments, are also provided.

Abstract: Methods for administering combinations of compositions comprising anti-S1P antibodies or antibody fragments and modulators of sphingolipid metabolic pathway enzymes are described. Such methods allow aberrant or undesirable levels of S1P to be reduced in patients known or suspected to have a disease or disorder correlated with aberrant S1P levels, and thus will be useful in treating such diseases and disorders.

Abstract: Methods for designing optimized antibodies, including optimized humanized or human antibodies, to target bioactive lipids are provided. These methods may be performed in silico and may be intended to enhance binding affinity of an antibody to its original target lipid, and/or to alter binding specificity. Antibodies produced by these methods are also provided, as are methods for using them.

Abstract: Methods for designing optimized antibodies, including optimized humainized or human antibodies, to target bioactive lipids are provided. These methods may be performed in silico and may be intended to enhance binding affinity of an antibody to its original target lipid, and/or to alter binding specificity. Antibodies produced by these methods are also provided, as are methods for using them.

Abstract: The present invention provides crystalline forms of an anti-LPA antibody or fragment thereof, which may further comprise a lipid ligand of said antibody and/or salts, metals, or co-factors. Methods for making such crystals and co-crystals are provided, as are methods of using structural information in antibody design or optimization. Methods for designing a humanized antibody to a lipid are provided. These methods may be performed in silico and may be intended to enhance binding affinity of an antibody to its original target lipid, and/or to alter binding specificity. Optimized variant anti-LPA antibodies are also provided.

Abstract: Monoclonal antibodies to platelet activating factor (PAF) are described, along with methods for their production and use. Such antibodies can be formulated and used for therapeutic purposes, as well as for diagnosis and detection.

Abstract: Methods for designing optimized antibodies, including optimized humanized or human antibodies, to target bioactive lipids are provided. These methods may be performed in silico and may be intended to enhance binding affinity of an antibody to its original target lipid, and/or to alter binding specificity. Antibodies produced by these methods are also provided, as are methods for using them.

Abstract: The present invention provides crystalline forms of an anti-lipid antibody or fragment thereof, which may further comprise a lipid ligand of said antibody and/or salts, metals, or co-factors. Methods for making such crystals and co-crystals are provided. The lipid may be a bioactive lipid, including sphingolipids such as S1P. X-ray coordinates of such a crystal are provided, as are methods of using this information in antibody design or optimization. Methods for designing a humanized antibody to a lipid are provided. These methods may be performed in silico and may be intended to enhance binding affinity of an antibody to its original target lipid, and/or to alter binding specificity. Antibodies produced by these methods are also provided.

Abstract: Methods for designing a humanized antibody to platelet activating factor are provided. These methods may be performed in silico.

Abstract: Compositions and methods for making and using anti-LPA agents, for example, monoclonal antibodies, are described. Variable domain and complementarity determining region amino acid sequences of several monoclonal antibodies against LPA are disclosed, as is a consensus anti-LPA monoclonal antibody variable domain sequence.